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INTRODUCTION
The prognosis of high-risk neuroblastoma after conventional
chemotherapy is generally poor (1-3). Therefore, a strategy
using high-dose chemotherapy and autologous stem cell res-
cue (HDCT/ASCR) has been explored to improve the prog-
nosis of patients with high-risk neuroblastoma (2-5). This
strategy is based on the hypothesis that dose escalation might
improve the survival of children with high-risk neuroblas-
toma. The results of randomized trials comparing HDCT/
ASCR with chemotherapy alone showed a better event-free
survival (EFS) in the HDCT/ASCR arm than in the contin-
uous chemotherapy arm (3, 6). However, the overall EFS was
unsatisfactory.
In this context, a few studies have examined the efficacy of
double or triple tandem HDCT/ASCR procedures to further
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Efficacy of Tandem High-Dose Chemotherapy and Autologous Stem
Cell Rescue in Patients Over 1 Year of Age with Stage 4 
Neuroblastoma: The Korean Society of Pediatric Hematology-Oncology
Experience Over 6 Years (2000-2005)
The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue
(HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients
over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from Jan-
uary 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hema-
tology-Oncology registry. All patients who were assigned to receive HDCT/ASCR
at diagnosis were retrospectively analyzed to investigate the efficacy of single or tan-
dem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tan-
dem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem
HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four
and 38 patients in the single or tandem HDCT group remained event free with a medi-
an follow-up of 56 (24-88) months. When the survival rate was analyzed according
to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival±95%
confidence intervals was higher in the tandem HDCT group than in the single HDCT
group (51.2±12.4% vs. 31.3±11.5%, P=0.030). The results of the present study
demonstrate that the tandem HDCT/ASCR strategy is significantly better than the
single HDCT/ASCR strategy for improved survival in the treatment of high-risk neu-
roblastoma patients.
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(7-9). George et al. (7) and Sung et al. (8) carried out a sin-
gle arm trial of tandem HDCT/ASCR as consolidation thera-
py and reported improved long-term survival with acceptable
toxicity. Kletzel et al. (9) also conducted a single arm trial of
triple tandem HDCT/ASCR and reported improved survival.
These studies demonstrated that further dose escalation might
result in additional improvements in the EFS of high-risk
neuroblastoma patients. However, there is no study that has
compared the efficacy of single and tandem HDCT/ASCR for
the treatment of high-risk neuroblastoma. Therefore, the pre-
sent study retrospectively compared the efficacy of single and
tandem HDCT/ASCR and showed that the tandem HDCT/
ASCR strategy might be better than the single HDCT/ASCR
strategy in terms of the EFS in patients with high-risk neu-
roblastoma. 
MATERIALS AND METHODS 
Patients
From January 2000 to December 2005, patients with newly
diagnosed stage 4 neuroblastoma over 1 yr of age at diagno-
sis were enrolled in the Korean Society of Pediatric Hematol-
ogy-Oncology (KSPHO) registry. In the present study, the pa-
tients who were assigned to receive single or tandem HDCT/
ASCR at diagnosis, as consolidation therapy after induction
therapy, were analyzed to investigate the efficacy of tandem
HDCT/ASCR compared to single HDCT/ASCR. Patients who
were assigned to receive HDCT/ASCR after relapse or progres-
sion were excluded from this analysis. Samsung Medical Cen-
ter Institutional Review Board approved the present study
(2008-07-002). 
Assessment of disease status
The diagnosis of neuroblastoma was made based on either
histological examination of tumor specimens or bone marrow
infiltration with neuroblastoma cells and elevated urine cat-
echolamine levels. The extent of the disease was evaluated
using computerized tomography, a technetium-99 (
99Tc) bone
scan, bilateral bone marrow aspirates and biopsy specimens,
and an iodine-131 or 123-metaiodobenzylguanidine scan; the
patients were staged according to the international neuroblas-
toma staging system (INSS) (10). However, the N-myc copy
number and tumor karyotype were not routinely evaluated.
Induction therapy
A variety of chemotherapy regimens were employed for
induction treatment (Table 1). Definitive surgery was usually
performed after 3-6 cycles of preoperative chemotherapy,
except for those patients who had surgical resection of their pri-
mary tumor before the administration of induction chemother-
apy. After surgery, 1-5 cycles of postoperative chemotherapy
was given prior to HDCT/ASCR. Radiotherapy was given to
patients with gross residual tumor after surgery. However, in
a few centers, radiotherapy was given to all patients regardless
of the resectability of the tumor. The timing of radiotherapy
was after surgery or after HDCT/ASCR. Peripheral blood stem
cells were usually collected during the recovery phase after
chemotherapy following surgery. 
HDCT and ASCR
After the completion of induction therapy, the patients
underwent single or tandem HDCT/ASCR as consolidation
treatment according to the assignment at diagnosis. Patients
with tumor progression prior to HDCT/ASCR received sal-
vage treatment and patients whose parents refused to proceed
to HDCT/ASCR for fear of toxicity and death were treated
with conventional chemotherapy alone. A variety of HDCT
regimens were employed (Table 1). In the tandem group, a
second HDCT/ASCR was usually given if the platelet count
exceeded 50×10
9/L after the first HDCT/ASCR without a
transfusion requirement and with no evidence of significant
organ dysfunction. Approximately half of the collected stem
cells were infused for marrow rescue at each HDCT session.
Post-HDCT treatment
Patients who underwent HDCT/ASCR received 13-cis-re-
tinoic acid for the possible minimal residual tumor cells. Dif-
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HDCT, high-dose chemotherapy; CEDC, cisplatinum+etoposide+doxoru-
bicin+cyclophosphamide; ICE, ifosfamide+carboplatin+etoposide; CDV,
cyclophosphamide+doxorubicin+vincristine; CE, cisplatinum+ etoposide;
CEM, carboplatin+etoposide+melphalan; TBI, total body irradiation; BM,
busulfan+melphalan; CTM, carboplatin+thiotepa+melphalan.
Regimens Single group Tandem group
Induction regimen (n=70) (n=71)
CEDC 45 (64.3%) 37 (52.1%)
CEDC/ICE 2 (2.9%) 26 (36.6%)
CDV/CE 6 (8.6%) 5 (7.0%)
Others 17 (24.3%) 3 (4.2%)
First HDCT regimen (n=57)  (n=66)
CEM 30 (52.6%) 10 (15.2%)
CEM-TBI 9 (15.8%) 19 (28.8%)
CEC 7 (12.3%) 30 (45.5%)
Others 11 (19.3%) 7 (10.6%)
Second HDCT regimen (n=4) (n=59)
TM-TBI 1 (25.0%) 17 (28.8%)
BM 1 (25.0%) 17 (28.8%)
CEM-TBI 0 (0%) 6 (10.2%)
CTM 0 (0%) 6 (10.2%)
CEM 0 (0%) 5 (8.5%)
Others 2 (50.0%) 8 (13.6%)
Table 1. Induction chemotherapy and HDCT regimensferentiation therapy with 13-cis-retinoic acid was usually ini-
tiated 60-90 days after the last HDCT/ASCR. Some patients
received immunotherapy using interleukin-2 according to the
physician's judgments. In some centers, local radiotherapy was
given after the HDCT/ASCR.
Response criteria
The international response criteria were used to evaluate
the treatment response (10). Briefly, complete response (CR)
was defined as no identifiable tumor with normal catechola-
mine levels. Very good partial response (VGPR) was defined
as a decrease in the primary tumor by 90-99% with normal
catecholamine levels with or without any residual 
99Tc bone
changes. Partial response (PR) was defined as a reduction of
the primary tumor and metastatic tumor by more than 50%.
Stable disease (SD) and minor response (MR) were responses
of less than 50%. Progressive disease (PD) indicated progres-
sion at any preexisting tumor site or appearance of a new lesion.
Statistics
The survival rate along with the 95% confidence interval
(CI) was estimated using the Kaplan-Meier method. An event
was defined as the occurrence of a relapse, progression or treat-
ment-related mortality (TRM). The differences in the survival
rates between the two groups were compared using the log-
rank test. The differences in the frequencies of the clinical and
biological factors between the two groups were compared
using the Pearson chi-square test. The differences in the levels
of tumor markers were compared using the Mann-Whitney U
test. The differences in the ANC and platelet recovery between
the first and second HDCT/ASCR were analyzed using a pair-
ed t-test. Multivariate analyses including the prognostic fac-
tors at diagnosis for EFS were performed using the Cox regres-
sion analysis. Pvalues <0.05 were considered significant.
RESULTS
Patient characteristics 
From January 2000 to December 2005, a total of 161 pa-
tients over 1 yr of age at diagnosis with newly diagnosed stage
4 neuroblastoma were enrolled in the KSPHO registry by
24 hospitals. A total of 141 out of 161 patients enrolled in
the KSPHO registry by 20 hospitals were assigned at diag-
nosis to receive single or tandem HDCT/ASCR (70 and 71
patients, respectively) as consolidation therapy after induc-
tion therapy. While some hospitals adopted one of the two
(single or tandem, 6 and 8 hospitals, respectively) strategies,
6 hospitals adopted both strategies according to the status
of patients at diagnosis or the study period. Table 2 lists the
clinical and biological characteristics of the patients. Although
a higher proportion of patients had bone metastasis in the tan-
dem group compared to the single group, no other significant
differences were observed for a variety of clinical and biolog-
ical characteristics between the single and tandem group. 
Induction treatment
The CEDC regimen was most commonly used in both the
single and tandem groups (Table 1). Gross total removal was
possible in about half of the patients (51.7% and 47.9% in
single and tandem group, respectively, P=NS). Local radio-
therapy was given to a greater proportion of patients in the
tandem group than in the single group (74.6% and 54.3%
in single and tandem group, respectively, P=0.012). A sim-
ilar proportion of patients in both groups were in the CR or
VGPR categories prior to the HDCT/ASCR (73.7% and
74.6%, in single and tandem group, respectively, P=NS). Fig.
1 shows the flow of patients from diagnosis through the tan-
dem HDCT/ASCR. During induction treatment, 6 progres-
sions, 1 TRM and 1 renal insufficiency occurred, and the par-
ents of 5 patients refused to proceed to the scheduled HDCT/
ASCR in the single group. In the tandem group, 3 progres-
sions occurred prior to HDCT/ASCR and the parents of 2
patients refused to proceed to the scheduled HDCT/ASCR.
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*Median (Range).
LDH, lactate dehydrogenase; NSE, neuro-specific enolase; VMA, vanil-
lylmandelic acid.
Characteristics
Single group
(n=70)
Tandem group
(n=71)
P value
Sex 0.076
Female 35 (50.0%) 25 (35.2%)
Male 35 (50.0%) 46 (64.8%)
Age 39 (13-159)* 36 (13-144) 0.370
Primary site 0.780
Abdomen 60 (85.7%) 62 (87.3%)
Others 10 (14.3%) 9 (12.7%)
Bone metastasis 44 (62.9%) 58 (81.7%) 0.012
Bone marrow metastasis 50 (71.4%) 59 (83.1%) 0.098
N-myc 0.464
Not amplified 16 (59.3%) 31 (50.8%)
Amplified (≥3 copies) 11 (40.7%) 30 (49.2%)
Unknown 43 10
Pathology 0.856
Favorable 6  (20.7%) 11  (22.4%)
Unfavorable 23 (79.3%) 30 (77.6%)
Unknown 41 30
LDH (U/L) 1,312 1,483 0.289
(191-17,625) (176-9,944)
NSE (ng/mL) 192  181  0.662
(12-7,210) (12-1,081)
Ferritin (ng/mL) 241  324  0.074
(36-1,196) (20-6,690)
24-hr VMA (mg/day) 9.3 11.2  0.992
(0.4-99.0) (0.1-170.8)
Table 2. Clinical and biological characteristics at diagnosisHDCT/ASCR
Fifty-seven (81.4%) out of 70 patients in the single group
proceeded to the HDCT/ASCR as assigned at diagnosis. Four
of them received a second HDCT because the tumor pro-
gressed after the first HDCT (n=3) or the patients were not
in CR (n=1). In the tandem group, 66 (93.0%) out of 71
patients proceeded to the first HDCT/ASCR as assigned at
diagnosis, however, 7 of them could not proceed to the second
HDCT/ASCR due to tumor progression after first HDCT
(n=1), TRM during the first HDCT (n=2), refusal by par-
ents (n=3) and an insufficient number of stem cells for res-
cue in the second HDCT (n=1). Therefore, 59 (83.1%) out of
71 patients in the tandem group received the tandem HDCT/
ASCR as assigned at diagnosis. Interim conventional chemoth-
erapy was given between the first and second HDCT in 6
patients because they were in PR after the first HDCT. A total
of 123 patients underwent at least one HDCT/ASCR and 63
patients underwent tandem HDCT/ASCR. 
The CEM regimen in the single group and the CEC regi-
men in the tandem group were most commonly used for the
first HDCT (Table 1). TM-TBI and BM regimens were most
frequently used for the second HDCT. Total body irradiation
(TBI) was included in the HDCT regimen in a significantly
higher proportion of patients in the tandem group than in the
single group (63.6% vs. 29.8%, P<0.001). In the tandem gro-
up, the TBI was administered as a part of the HDCT/ASCR
in 38 (15 in the first and 23 in the second HDCT) out of 59
patients who completed the tandem HDCT/ASCR, but not
in the remaining 21 patients. In the tandem HDCT/ASCR,
the median interval from the first infusion of stem cells to the
initiation of the second HDCT was 90 days (range 43-261)
and the interval was less than 120 days in 81.4% of the pati-
ents. When the patients who received interim chemotherapy
between the first and second HDCT were excluded from the
analyses, the median interval was 86 days (range 43-173) and
the interval was less than 120 days in 90.6% of the patients.
A median of 3.5×10
6 CD34
+ cells/kg (range 0.6-48.5) were
infused for the first HDCT/ASCR, and the median time requi-
red to reach an ANC of 0.5×10
9/L and a platelet count of
20×10
9/L, without transfusion over the previous 7 days, was
11 days (range 8-52) and 23 days (range 10-362), respective-
ly. A median of 2.9×10
6 CD34
+ cells/kg (range 0.2-42.5)
were infused for the second HDCT/ASCR and the median
time required to reach an ANC of 0.5×10
9/L and a platelet
count of 20×10
9/L was 11 days (range 8-27) and 34 days
(range 17-417), respectively. When the analysis was con-
fined to only those patients who received tandem transplan-
tation, the platelet recovery was significantly delayed after the
second transplantation compared to the first (median 23 days
versus 34 days, P=0.003). 
A total of 11 (8.9%) TRMs (9 in single group and 2 in tan-
dem group) were noted during the first HDCT/ASCR and
were attributed to viral pneumonia (n=4), pulmonary hem-
orrhage (n=3), sepsis (n=2), hepatic veno-occlusive disease
(VOD) (n=1), and an unknown cause (n=1). A total of 6 (9.5
%) TRMs were noted during the second HDCT/ASCR and
were attributed to VOD (n=3), myocarditis (n=1), acute renal
failure (n=1), and sepsis (n=1). Five of the 6 TRMs during
the second HDCT occurred in patients who received TBI.
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All patients
(n=141)
Single group
(n=70)
Single HDCT
(n=57)
No HDCT
(n=13)
Single HDCT
(n=7)
Tandem HDCT
(n=59)
No HDCT
(n=5)
Tandem group
(n=71)
27 Relapse/Progressions
9 TRMs during HDCT
21 Relapse free
6 Progressions prior to HDCT
1 TRM prior HDCT
1 Renal insufficiency
5 Refusals of HDCT
19 Relapse/Progressions
6 TRMs during 2nd HDCT
34 Relapse free
1 Progression after 1st HDCT
2 TRMs during 1st HDCT
3 Refusals of 2nd HDCT
1 Insufficient cell dose
3 Progressions prior to HDCT
2 Refusals of HDCT
2 Relapses
2 Relapse free
3 Relapse/Progressions
3 Relapse free
2 Relapse free
Fig. 1. Flow of patients. Fifty-seven (81.4%) out of 70 patients in the single group proceeded to the HDCT/ASCR as assigned at diagno-
sis. In the tandem group, 66 (93.0%) out of 71 patients proceeded to the first HDCT/ASCR and 59 (83.1%) patients received the second
HDCT/ASCR as assigned at diagnosis.While all 5 TRMs occurred in 15 patients who received TBI
during the first HDCT, there was no TRM among the 23
patients who received TBI during the second HDCT (P=
0.006). Thyroid cancer developed in one patient in the tandem
group; however, this patient received only the first HDCT/
ASCR and did not proceed to the second HDCT/ASCR due
to parental fear of toxicity and death. Otherwise, there were
no other secondary malignancies observed in the present study. 
Survival of patients
The median follow-up duration of all living patients was 56
months (range 24-88) from diagnosis. The tumor relapsed
or progressed in 36 out of 70 patients and 10 TRMs occurred
in the single group. The remaining 24 patients remained
event free with a median follow-up of 68 months (range 24-
85) from diagnosis. For the tandem group, the tumor relapsed
or progressed in 25 out of 71 patients and 8 TRMs occurred.
The remaining 38 patients remained event free with a medi-
an follow-up of 41 months (range 28-88) from diagnosis.
When the survival rate was analyzed according to intent-to-
treat at diagnosis, the probability of 5-yr EFS after diagnosis
was higher in the tandem group than in the single group
(51.2%±12.4% vs. 31.3%±11.5%, P=0.030, Fig. 2A).
When the analysis was confined to the 123 patients who
proceeded to HDCT/ASCR as assigned at diagnosis (57 sin-
gle and 66 tandem), the probability of 5-yr RFS after the
first HDCT was higher in the tandem group than in the
single group with  borderline significance (59.1%±13.5%
vs.41.6%±14.5%, P=0.099, Fig. 2B). However, the dif-
ference became significant when the analysis was confined
to only patients who were not in CR prior to the first HDCT
(55.7%±17.0% vs. 0%, P=0.012, Fig. 2C). The probabil-
ity of RFS after the tandem HDCT was significantly higher
in the TBI group than in non-TBI group (70.5%±16.6%
vs. 47.4%±23.1%, P=0.049) although the TRM rate was
slightly higher in the TBI group than in the non-TBI group
(5/38 vs. 1/21, P=NS). Multivariate analyses including the
prognostic factors at diagnosis for EFS revealed that tandem
HDCT /ASCR treatment was the only independent favorable
prognostic factor associated with the EFS (hazard ratio 0.16,
95% confidence interval 0.03-0.91, P=0.039; Table 3). 
DISCUSSION
Although the strategy of using HDCT/ASCR has improved
the survival of patients with high-risk neuroblastoma, the sur-
vival rate after a single HDCT/ASCR has been unsatisfacto-
ry (2-5). Therefore, investigators have examined the efficacy
of tandem HDCT/ASCR to further improve the outcome of
high-risk neuroblastoma patients, and have shown that tan-
dem HDCT/ASCR is a feasible approach which might result
in further improvements in the survival of high-risk neurob-
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Fig. 2. Results of the Kaplan-Meier analysis. (A) When the survival
rate was analyzed according to intent-to-treat at diagnosis, the
probability of the 5-yr EFS after diagnosis was higher in the tandem
group than in the single group (51.2±12.4% vs. 31.3±11.5%,
P=0.030). (B) When the analysis was confined to 123 patients who
proceeded to HDCT/ASCR as assigned at diagnosis, the probabili-
ty of 5-yr RFS after the first HDCT was higher in the tandem group
than in the single group with borderline significance (59.7±13.5%
vs. 41.6±14.5%, P=0.099). (C) However, the difference became
significant when the analysis was confined to only patients who
were not in CR prior to the first HDCT (55.7±17.0% vs. 0%,
P=0.012). 
A
C
Blastoma patients (7-9). However, no study has compared the
efficacy of single with tandem HDCT/ASCR for the treat-
ment of high-risk neuroblastoma. Therefore, the present study
retrospectively compared the efficacy of single and tandem
HDCT/ASCR. The results showed that the tandem HDCT/
ASCR strategy is significantly better than single HDCT/
ASCR strategy for improved survival of patients with high-
risk neuroblastoma. The survival rate in the tandem group, in
the present study, was similar to other prior studies that have
reported on the tandem double and tandem triple HDCT/
ASCR strategies (7-9). 
In the present study, the number of cases with tumor pro-
gression prior to the first HDCT/ASCR, and the number of
TRM during the first HDCT were higher in the single group
than in the tandem group. These findings suggest that the
quality of medical treatment might not have been the same
for the single and tandem groups. These findings might have
affected the outcome of the patients (worse EFS in the single
group) and create doubt as to whether the tandem HDCT/
ASCR itself resulted in a better outcome compared to the sin-
gle HDCT/ASCR in the present study. However, when the
analysis was confined to the patients that successfully preced-
ed to HDCT/ASCR, as assigned at diagnosis, the probabili-
ty of the 5-yr RFS, after the first HDCT, was still higher in
the tandem group than in the single group, particularly in
the patients who were not in CR prior to the first HDCT.
Taken together, these findings suggest that the tandem HDC
T/ASCR strategy can provide better outcomes in patients with
high-risk neuroblastoma than single HDCT/ASCR strategy. 
While neutrophil recovery after the second HDCT/ASCR
was as rapid as after the first HDCT/ASCR, the platelet recov-
ery was significantly delayed after the second HDCT/ASCR
compared to the first HDCT/ASCR. However, this was not
clinically significant. A total of 6 TRMs were noted during
the second HDCT/ASCR in the tandem group. However, this
TRM rate might be acceptable considering that the tumor
relapsed in 19 patients even after the tandem HDCT/ASCR.
Taken together, these findings suggest that the tandem HD
CT/ASCR strategy can provide better outcomes than single
HDCT/ASCR strategy despite the additional toxicity risks
during the second HDCT/ASCR.
TBI was administered as a part of the HDCT/ASCR in 38
out of 59 patients who completed the tandem HDCT, but not
in the remaining 21 patients. The probability of RFS after the
tandem HDCT was significantly higher in the TBI group
compared to the non-TBI group, although the TRM rate
during the second HDCT/ASCR was slightly higher in the
TBI group than in the non-TBI group. Of note is that there
was no TRM during the second HDCT in the patients who
received TBI during the second HDCT. All TRMs during
the second HDCT in the TBI group occurred in patients
who received TBI during the first HDCT. These findings
are consistent with the findings in the report by Sung et al
(8). They reported that TBI during the first HDCT/ASCR
was significantly associated with a higher TRM rate in the
second HDCT; they recommended that TBI should be
included in the second HDCT/ASCR if TBI is to be includ-
ed in the tandem HDCT regimen. Taken together, admin-
istration of TBI was associated with a higher RFS despite
the high TRM rate, and TBI might improve the EFS if TBI
is included in the second HDCT/ASCR. 
Intensive tandem HDCT/ASCR and radiation therapy (par-
ticularly TBI) may improve the survival of patients with high-
risk neuroblastoma, but may also increase the frequency and
severity of long-term side effects such as a secondary malig-
nancy (11-13). Although no secondary malignancy developed
in the patients who completed the tandem HDCT/ASCR, a
longer follow-up will be needed to consider this possibility.
The optimal combination of regimens for the tandem HDCT
has yet to be determined. Further study will be needed to
reduce the TRM rate during the second HDCT/ASCR as well
as the long-term side effects whilst maintaining or reducing
the relapse rate after intensive tandem HDCT/ASCR. 
In summary, the results of the present retrospective study
demonstrated that the tandem HDCT/ASCR strategy is sig-
nificantly better than the single HDCT/ASCR strategy in
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Cox regression analysis; HR, hazard ratio; CI, confidence interval.
Univariate analysis
HR 95% CI P value
Multivariate analysis
HR 95% CI P value
Age >3 yr 1.63 1.02-2.61 0.042 1.35 0.40-4.80 0.664
Abdominal tumor 1.31 0.67-2.54 0.431 1.64 0.33-8.16 0.548
N-myc amplification 1.63 0.89-3.00 0.114 1.06 0.39-2.85 0.909
Unfavorable pathology 1.51 0.73-3.14 0.269 1.35 0.44-4.12 0.600
BM involvement 1.41 0.80-2.48 0.231 5.84 0.98-34.93 0.053
Bone involvement 1.21 0.73-2.01 0.467 0.93 0.25-3.48 0.916
LDH ≥median 1.11 0.69-1.78 0.669 0.63 0.18-2.26 0.480
Ferritin ≥median 1.26 0.79-2.01 0.330 0.98 0.33-2.29 0.974
NSE ≥median 1.19 0.74-1.90 0.465 1.43 0.46-4.42 0.539
24-hr VMA≥median 1.32 0.82-2.22 0.259 1.07 0.36-3.18 0.908
Intent to apply Tandem HDCT at Dx 0.62 0.39-0.96 0.034 0.16 0.03-0.91 0.039
Table 3. Multivariate analyses including the prognostic factors at diagnosis for EFS
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terms of survival for the treatment of patients with high-risk
neuroblastoma, particularly when the patient is not in CR
prior to the HDCT/ASCR. A randomized prospective study
will be needed in the future to explore the safety and efficacy
of tandem HDCT/ASCR compared to single HDCT/ASCR,
and to confirm our findings. 
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